ACTA1 and cancer: Expression of α-SMA is commonly used as a marker for TDFs, and is associated with poor prognosis in a range of cancers, including OAC10, 31, oesophageal squamous cell carcinoma32, colorectal6, breast33, and head and neck cancers34.